Fallopian tube cancer is rare, accounting for about 1% of gynecologic cancers. It's often found at advanced stages because early symptoms are vague. Treatment typically involves surgery to remove reproductive organs plus chemotherapy, similar to ovarian cancer. Most fallopian tube cancers are high-grade serous carcinomas.
What's actually going on in research
Trials are testing PARP inhibitors for BRCA-mutated cancers, immune checkpoint inhibitors often combined with chemotherapy or targeted drugs, antibody-drug conjugates that deliver chemotherapy directly to cancer cells, and new platinum-based regimens. Researchers are also studying whether fallopian tube cancer should be treated identically to ovarian cancer or requires distinct approaches.
PARP inhibitors
Olaparib and other PARP inhibitors are FDA-approved for BRCA-mutated ovarian and fallopian tube cancers. Trials are testing them earlier in treatment and in combination with other drugs.
Antibody-drug conjugates
Mirvetuximab soravtansine targets folate receptor alpha, which appears on many ovarian and fallopian tube cancer cells. It's approved for some ovarian cancers and being studied in fallopian tube cancer.
Immunotherapy combinations
Checkpoint inhibitors like pembrolizumab are being combined with chemotherapy, PARP inhibitors, or VEGF inhibitors. Early data suggest some combinations may work better than single drugs.
What to know before you search
Eligibility typically depends on cancer stage, prior treatments, BRCA mutation status, and performance status measuring how well you function day-to-day.
What types of trials are currently open
- Chemotherapy trials — Testing new platinum-based combinations or schedules, often comparing different drugs given with carboplatin and paclitaxel.
- Targeted therapy trials — Testing PARP inhibitors, VEGF inhibitors like bevacizumab, or antibody-drug conjugates, usually after chemotherapy or when cancer returns.
- Immunotherapy trials — Testing checkpoint inhibitors alone or combined with chemotherapy or targeted drugs.
- Maintenance trials — Testing whether continuing treatment after initial chemotherapy can delay cancer growth, often using PARP inhibitors or bevacizumab.
- Biomarker studies — Looking at tumor genetics to predict which treatments work best, especially for BRCA mutations and other DNA repair defects.
Recently added Fallopian Tube Cancer trials
Take an experimental vaccine designed to prevent ovarian cancer recurrence
Ovarian, fallopian tube, or primary peritoneal cancer, collectively referred to as ovarian cancer, remains the deadliest type of gynaecological cancer. The most common and aggressive form is called high-grade serous ovarian cancer. The main purpose of this study is to understand whether an experimental study vaccine, CryptiVax-1001, is safe when administered to patients with high-grade serous ovarian cancer (HGSOC). The study vaccine is a cancer vaccine, which aims to delay or possibly prevent the cancer from coming back. However, as this is the first study of the vaccine in patients, the primary purpose of this study is to assess the safety of the study vaccine. Following surgery and platinum-based chemotherapy participants may enter the trial and receive CryptiVax-1001 as an explorative maintenance therapy. The main purposes of this study are therefore to: * assess how well the study vaccine is tolerated and identify any side effects. * analyse the study vaccine's capacity to activate your immune system The study will test escalating dose levels of CryptiVax-1001 based on the safety evaluations to estimate appropriate future dose levels for CryptiVax-1001.
Share your treatment data in a gynecologic cancer registry
REGYNERA(dia)TION is an international, multicenter, ambispective observational patient registry of adults with recurrent gynecologic malignancies after prior radiotherapy who are treated or planned for reirradiation and/or total ablative strategies as part of routine clinical care. The registry does not assign treatment. Radiotherapy technique, dose, systemic therapy, surgery, metastasis-directed therapy, imaging, and follow-up are selected by the treating multidisciplinary team according to local standards and patient-specific factors. The registry will collect harmonized retrospective and prospective data on disease characteristics, prior radiotherapy, recurrence pattern, reirradiation or ablative treatment exposure, response, progression, survival, severe treatment-related morbidity, fistula events, and patient-reported outcomes where available.
Find Fallopian Tube Cancer trials matched specifically to you
Answer 3 quick questions and we'll show you trials that fit your situation.